In both breast cancer cell lines and primary cancer cells, the data show that PI3K, not MAPK, is the downstream effector that contributes most significantly to the ligand-driven HER2 signal in the CELx HSF test for these cancer cell samples. This evidence concerns the gene ERBB2 and cancer.